Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The rare disease specialist recently reported strong US demand
Thursday 27 Apr 2017 Author: Lisa-Marie Janes

Shire’s (SHP) dry eye disease treatment XIIDRA shot to success in the first four months of its debut in 2016, capturing 19% of market share in the US.

First quarter results on 2 May could provide a chance for Shire to update on sales momentum. Investors will also want to know if Roche is continuing to chip away at sales in Shire’s underperforming haemophilia franchise.

‹ Previous2017-04-27Next ›